Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding

ABSTRACT: Differential ChIP-Seq data monitoring changes in active enhancer marks (H3K27ac sites) after treatment with siGRHL2 in MCF7 and T47D breast cancer models. Comparing sites altered by treatment with siGRHL2 after 48hours revealed these sites to be enriched for Estrogen Receptor (ER) binding.

ORGANISM(S): Homo sapiens

PROVIDER: GSE123475 | GEO | 2018/12/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding

Project description:Knockdown of GRHL2 affects active enhancers (H3K27ac sites) enriched for ER binding

| PRJNA508818 | ENA

Transcriptional reprogramming underpinning resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer cell lines

Project description:To investigate the molecular mechanisms of resistance to ER downregulator and CDK4/6 inhibitors in ER+ breast cancer, we generated two cell lines, MCF7 and T47D, resistant to fulvestrant and abemaciclib after 6-8 months of exposure to increasing doses of the drug combination We performed gene expression profiling analysis using data obtained from RNA-seq of parental MCF7 or T47D and the respective fulvestrant and abemaciclib resistant cells

2023-06-05 | GSE227102 | GEO

CDK4/6 inhibitors in ER positive breast cancers

Project description:Gene expression levels were determined with control or PD-0332991 treatment MCF7, T47D cells were subject to DMSO/ PD-0332991 treatment . RNA was harvested at 120 hours post treatment and analyzed on Illumina microarrays

2016-08-01 | E-GEOD-80987 | biostudies-arrayexpress

Gene expression analyses of palbociclib treated ER+ breast cancer cell lines as assessed by RNA-seq

Project description:The goal of this study is to measure gene expression changes resulting over time of palbociclib treatment of T47D, MCF7, and CAMA1 ER+ breast cancer cell lines.

2020-12-28 | GSE148265 | GEO

CREBBP/EP300 acetyltransferase inhibition targets lineage specific enhancers to inhibit the proliferation of ER+ breast cancer cells [RNA-Seq]

Project description:MCF7, T47D, or ZR751 cells were treated with a CREBBP/EP300 acetyltransferase inhibitor CPI-1612 and/or Fulvestrant and expression changes were measured via RNA-seq

2022-03-04 | GSE190160 | GEO

ER/PR RIME Experiments in MCF7 and T47D cell lines

Project description:Immuno-precipitation followed by MS was performed using the RIME protocol in this study. Estrogen Receptor (ER) and Progestorone Receptor (PR) were targetted using antibodies. The experiments were performed in a quantitative manner using SILAC labelling. Cells grown in complete serum (estrogenic) conditions were compared against an cells in similar complete media, however supplemented with Progesterone (PG) or R5020 for 4 hours. Experiments were performed in MCF7 and T47D cell lines

2015-05-26 | PXD002104 | Pride

The role of Hippo pathway in ER positive breast cancer

Project description:We report the transcriptional difference of LATS1/2 gene knock out T47D cells with wild type control using RNA-seq technology. We further generated the chromatin binding of multiple proteins, including YAP, TEAD2, Estrogen receptor alpha, VGLL3 and several histone marks, as well as ATAC profiling between LATS1/2 gene knock out MCF7 cells with wild type control.

2022-01-11 | GSE181460 | GEO

The Phosphorylated Estrogen Receptor ? (ER) Cistrome Identifies a Subset of Active Enhancers Enriched for Direct ER-DNA Binding and the Transcription Factor GRHL2.

Project description:Posttranslational modifications are key regulators of protein function, providing cues that can alter protein interactions and cellular location. Phosphorylation of estrogen receptor ? (ER) at serine 118 (pS118-ER) occurs in response to multiple stimuli and is involved in modulating ER-dependent gene transcription. While the cistrome of ER is well established, surprisingly little is understood about how phosphorylation impacts ER-DNA binding activity. To define the pS118-ER cistrome, chromatin immunoprecipitation sequencing was performed on pS118-ER and ER in MCF-7 cells treated with estrogen. pS118-ER occupied a subset of ER binding sites which were associated with an active enhancer mark, acetylated H3K27. Unlike ER, pS118-ER sites were enriched in GRHL2 DNA binding motifs, and estrogen treatment increased GRHL2 recruitment to sites occupied by pS118-ER. Additionally, pS118-ER occupancy sites showed greater enrichment of full-length estrogen response elements relative to ER sites. In an in vitro DNA binding array of genomic binding sites, pS118-ER was more commonly associated with direct DNA binding events than indirect binding events. These results indicate that phosphorylation of ER at serine 118 promotes direct DNA binding at active enhancers and is a distinguishing mark for associated transcription factor complexes on chromatin.

| S-EPMC6336141 | biostudies-literature

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 and T47D RNAseq]

Project description:We performed RNA sequencing on T47D and MCF7 cells, both parental and abema- or abema/fulvestrant- resistant, treated with either control vehicle or 300 nM (MCF7) or 100 nM (T47D) INX-315 for 7 days

2023-11-22 | GSE243150 | GEO

H3K27Ac in MCF7 Y537S ER mutant cells and RNAseq with and without treatment with THZ1

Project description:H3K27Ac ChIP-seq in MCF7 Y537S ER mutant cells RNAseq analysis of MCF7 Y537S ER mutant cells treated with veh and THZ1

2018-02-15 | GSE106552 | GEO